Bifidobacterium quadruple live bacteria tablets

Developed for: active peptic ulcer disease
Investigated by: Hangzhou Grand Biologic Pharmaceutical, Inc. · Nanjing First Hospital, Nanjing Medical University · Renmin Hospital of Wuhan University · The First Affiliated Hospital of Nanchang University · The First Affiliated Hospital of Shanxi Medical University · The First Affiliated Hospital of Zhengzhou University
+3 more
· The First People's Hospital of Yunnan · Xi'an Central Hospital · Zhejiang Provincial Hospital of TCM

today NCT04034641 · Ph 4

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT04034641	Jun 2019 → Dec 2020	active peptic ulcer disease	Hangzhou Grand Biologic Pharmaceutical, Inc.	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Bifidobacterium quadruple live bacteria tablets	“Bifidobacterium quadruple live bacteria tablets (Si Lian Kang)” NCT04034641 ↗
Known as	Bifidobacterium tetrad live bacteria tablet	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04034641 ↗
Known as	Si Lian Kang	“Bifidobacterium quadruple live bacteria tablets (Si Lian Kang)” NCT04034641 ↗